nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—Cardio-respiratory arrest—Vandetanib—thyroid cancer	0.0547	0.0547	CcSEcCtD
Ceftazidime—Nephropathy—Vandetanib—thyroid cancer	0.041	0.041	CcSEcCtD
Ceftazidime—Gastrointestinal symptom NOS—Sorafenib—thyroid cancer	0.0224	0.0224	CcSEcCtD
Ceftazidime—Colitis—Vandetanib—thyroid cancer	0.0188	0.0188	CcSEcCtD
Ceftazidime—Lethargy—Vandetanib—thyroid cancer	0.0145	0.0145	CcSEcCtD
Ceftazidime—Skin exfoliation—Sorafenib—thyroid cancer	0.0126	0.0126	CcSEcCtD
Ceftazidime—Bronchospasm—Vandetanib—thyroid cancer	0.0121	0.0121	CcSEcCtD
Ceftazidime—Prothrombin level increased—Epirubicin—thyroid cancer	0.0119	0.0119	CcSEcCtD
Ceftazidime—Neutropenia—Vandetanib—thyroid cancer	0.0115	0.0115	CcSEcCtD
Ceftazidime—Prothrombin level increased—Doxorubicin—thyroid cancer	0.011	0.011	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Sorafenib—thyroid cancer	0.0109	0.0109	CcSEcCtD
Ceftazidime—Infestation—Vandetanib—thyroid cancer	0.0109	0.0109	CcSEcCtD
Ceftazidime—Infestation NOS—Vandetanib—thyroid cancer	0.0109	0.0109	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.0108	0.0108	CcSEcCtD
Ceftazidime—Renal failure—Vandetanib—thyroid cancer	0.0107	0.0107	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Vandetanib—thyroid cancer	0.0103	0.0103	CcSEcCtD
Ceftazidime—Haemoglobin—Vandetanib—thyroid cancer	0.00986	0.00986	CcSEcCtD
Ceftazidime—Haemorrhage—Vandetanib—thyroid cancer	0.00981	0.00981	CcSEcCtD
Ceftazidime—Erythema multiforme—Vandetanib—thyroid cancer	0.00927	0.00927	CcSEcCtD
Ceftazidime—Angiopathy—Vandetanib—thyroid cancer	0.0089	0.0089	CcSEcCtD
Ceftazidime—Local reaction—Epirubicin—thyroid cancer	0.0088	0.0088	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00861	0.00861	CcSEcCtD
Ceftazidime—Dysgeusia—Vandetanib—thyroid cancer	0.00836	0.00836	CcSEcCtD
Ceftazidime—Local reaction—Doxorubicin—thyroid cancer	0.00814	0.00814	CcSEcCtD
Ceftazidime—Vision blurred—Vandetanib—thyroid cancer	0.00805	0.00805	CcSEcCtD
Ceftazidime—Tremor—Vandetanib—thyroid cancer	0.008	0.008	CcSEcCtD
Ceftazidime—Thrombocytosis—Epirubicin—thyroid cancer	0.00783	0.00783	CcSEcCtD
Ceftazidime—Neutropenia—Sorafenib—thyroid cancer	0.00773	0.00773	CcSEcCtD
Ceftazidime—Oral candidiasis—Epirubicin—thyroid cancer	0.00767	0.00767	CcSEcCtD
Ceftazidime—Convulsion—Vandetanib—thyroid cancer	0.0074	0.0074	CcSEcCtD
Ceftazidime—Infestation NOS—Sorafenib—thyroid cancer	0.00737	0.00737	CcSEcCtD
Ceftazidime—Infestation—Sorafenib—thyroid cancer	0.00737	0.00737	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00731	0.00731	CcSEcCtD
Ceftazidime—Thrombocytosis—Doxorubicin—thyroid cancer	0.00725	0.00725	CcSEcCtD
Ceftazidime—Renal failure—Sorafenib—thyroid cancer	0.00725	0.00725	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00722	0.00722	CcSEcCtD
Ceftazidime—Jaundice—Sorafenib—thyroid cancer	0.00718	0.00718	CcSEcCtD
Ceftazidime—Oral candidiasis—Doxorubicin—thyroid cancer	0.00709	0.00709	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00697	0.00697	CcSEcCtD
Ceftazidime—Nervous system disorder—Vandetanib—thyroid cancer	0.00683	0.00683	CcSEcCtD
Ceftazidime—Thrombocytopenia—Vandetanib—thyroid cancer	0.00682	0.00682	CcSEcCtD
Ceftazidime—Skin disorder—Vandetanib—thyroid cancer	0.00677	0.00677	CcSEcCtD
Ceftazidime—Haemoglobin—Sorafenib—thyroid cancer	0.00665	0.00665	CcSEcCtD
Ceftazidime—Haemorrhage—Sorafenib—thyroid cancer	0.00662	0.00662	CcSEcCtD
Ceftazidime—Dermatitis atopic—Epirubicin—thyroid cancer	0.00658	0.00658	CcSEcCtD
Ceftazidime—Paraesthesia—Vandetanib—thyroid cancer	0.00626	0.00626	CcSEcCtD
Ceftazidime—Erythema multiforme—Sorafenib—thyroid cancer	0.00626	0.00626	CcSEcCtD
Ceftazidime—Flushing—Sorafenib—thyroid cancer	0.00614	0.00614	CcSEcCtD
Ceftazidime—Dermatitis atopic—Doxorubicin—thyroid cancer	0.00609	0.00609	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00602	0.00602	CcSEcCtD
Ceftazidime—Angiopathy—Sorafenib—thyroid cancer	0.006	0.006	CcSEcCtD
Ceftazidime—Immune system disorder—Sorafenib—thyroid cancer	0.00598	0.00598	CcSEcCtD
Ceftazidime—Injection site pain—Epirubicin—thyroid cancer	0.00596	0.00596	CcSEcCtD
Ceftazidime—Pain—Vandetanib—thyroid cancer	0.00596	0.00596	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Vandetanib—thyroid cancer	0.0057	0.0057	CcSEcCtD
Ceftazidime—Dysgeusia—Sorafenib—thyroid cancer	0.00564	0.00564	CcSEcCtD
Ceftazidime—Injection site pain—Doxorubicin—thyroid cancer	0.00552	0.00552	CcSEcCtD
Ceftazidime—Abdominal pain—Vandetanib—thyroid cancer	0.00551	0.00551	CcSEcCtD
Ceftazidime—Body temperature increased—Vandetanib—thyroid cancer	0.00551	0.00551	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.00536	0.00536	CcSEcCtD
Ceftazidime—Angioedema—Sorafenib—thyroid cancer	0.00526	0.00526	CcSEcCtD
Ceftazidime—Leukopenia—Sorafenib—thyroid cancer	0.00516	0.00516	CcSEcCtD
Ceftazidime—Inflammation—Epirubicin—thyroid cancer	0.00502	0.00502	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.00495	0.00495	CcSEcCtD
Ceftazidime—Pruritus—Vandetanib—thyroid cancer	0.00493	0.00493	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00487	0.00487	CcSEcCtD
Ceftazidime—Vaginal inflammation—Epirubicin—thyroid cancer	0.00487	0.00487	CcSEcCtD
Ceftazidime—Diarrhoea—Vandetanib—thyroid cancer	0.00477	0.00477	CcSEcCtD
Ceftazidime—Anaphylactic shock—Sorafenib—thyroid cancer	0.0047	0.0047	CcSEcCtD
Ceftazidime—Colitis—Epirubicin—thyroid cancer	0.00468	0.00468	CcSEcCtD
Ceftazidime—Candida infection—Epirubicin—thyroid cancer	0.00465	0.00465	CcSEcCtD
Ceftazidime—Skin exfoliation—Epirubicin—thyroid cancer	0.00465	0.00465	CcSEcCtD
Ceftazidime—Inflammation—Doxorubicin—thyroid cancer	0.00465	0.00465	CcSEcCtD
Ceftazidime—Nervous system disorder—Sorafenib—thyroid cancer	0.00461	0.00461	CcSEcCtD
Ceftazidime—Dizziness—Vandetanib—thyroid cancer	0.00461	0.00461	CcSEcCtD
Ceftazidime—Thrombocytopenia—Sorafenib—thyroid cancer	0.0046	0.0046	CcSEcCtD
Ceftazidime—Vaginal infection—Epirubicin—thyroid cancer	0.0046	0.0046	CcSEcCtD
Ceftazidime—Aplastic anaemia—Epirubicin—thyroid cancer	0.00457	0.00457	CcSEcCtD
Ceftazidime—Skin disorder—Sorafenib—thyroid cancer	0.00457	0.00457	CcSEcCtD
Ceftazidime—Vaginal inflammation—Doxorubicin—thyroid cancer	0.00451	0.00451	CcSEcCtD
Ceftazidime—Coma—Epirubicin—thyroid cancer	0.00445	0.00445	CcSEcCtD
Ceftazidime—Vomiting—Vandetanib—thyroid cancer	0.00443	0.00443	CcSEcCtD
Ceftazidime—Rash—Vandetanib—thyroid cancer	0.00439	0.00439	CcSEcCtD
Ceftazidime—Dermatitis—Vandetanib—thyroid cancer	0.00439	0.00439	CcSEcCtD
Ceftazidime—Headache—Vandetanib—thyroid cancer	0.00437	0.00437	CcSEcCtD
Ceftazidime—Colitis—Doxorubicin—thyroid cancer	0.00433	0.00433	CcSEcCtD
Ceftazidime—Candida infection—Doxorubicin—thyroid cancer	0.0043	0.0043	CcSEcCtD
Ceftazidime—Skin exfoliation—Doxorubicin—thyroid cancer	0.0043	0.0043	CcSEcCtD
Ceftazidime—Vaginal infection—Doxorubicin—thyroid cancer	0.00425	0.00425	CcSEcCtD
Ceftazidime—Aplastic anaemia—Doxorubicin—thyroid cancer	0.00423	0.00423	CcSEcCtD
Ceftazidime—Nausea—Vandetanib—thyroid cancer	0.00414	0.00414	CcSEcCtD
Ceftazidime—Coma—Doxorubicin—thyroid cancer	0.00412	0.00412	CcSEcCtD
Ceftazidime—Phlebitis—Epirubicin—thyroid cancer	0.0041	0.0041	CcSEcCtD
Ceftazidime—Thrombophlebitis—Epirubicin—thyroid cancer	0.00408	0.00408	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00406	0.00406	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00404	0.00404	CcSEcCtD
Ceftazidime—Pain—Sorafenib—thyroid cancer	0.00402	0.00402	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00384	0.00384	CcSEcCtD
Ceftazidime—Phlebitis—Doxorubicin—thyroid cancer	0.0038	0.0038	CcSEcCtD
Ceftazidime—Hot flush—Epirubicin—thyroid cancer	0.00378	0.00378	CcSEcCtD
Ceftazidime—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00378	0.00378	CcSEcCtD
Ceftazidime—Menopausal symptoms—Epirubicin—thyroid cancer	0.00375	0.00375	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00374	0.00374	CcSEcCtD
Ceftazidime—Urticaria—Sorafenib—thyroid cancer	0.00373	0.00373	CcSEcCtD
Ceftazidime—Abdominal pain—Sorafenib—thyroid cancer	0.00372	0.00372	CcSEcCtD
Ceftazidime—Body temperature increased—Sorafenib—thyroid cancer	0.00372	0.00372	CcSEcCtD
Ceftazidime—Renal impairment—Epirubicin—thyroid cancer	0.00371	0.00371	CcSEcCtD
Ceftazidime—Lethargy—Epirubicin—thyroid cancer	0.00361	0.00361	CcSEcCtD
Ceftazidime—Hot flush—Doxorubicin—thyroid cancer	0.0035	0.0035	CcSEcCtD
Ceftazidime—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00347	0.00347	CcSEcCtD
Ceftazidime—Hypersensitivity—Sorafenib—thyroid cancer	0.00346	0.00346	CcSEcCtD
Ceftazidime—Renal impairment—Doxorubicin—thyroid cancer	0.00344	0.00344	CcSEcCtD
Ceftazidime—Lethargy—Doxorubicin—thyroid cancer	0.00334	0.00334	CcSEcCtD
Ceftazidime—Pruritus—Sorafenib—thyroid cancer	0.00333	0.00333	CcSEcCtD
Ceftazidime—Diarrhoea—Sorafenib—thyroid cancer	0.00322	0.00322	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00318	0.00318	CcSEcCtD
Ceftazidime—Dizziness—Sorafenib—thyroid cancer	0.00311	0.00311	CcSEcCtD
Ceftazidime—Eosinophilia—Epirubicin—thyroid cancer	0.00302	0.00302	CcSEcCtD
Ceftazidime—Vomiting—Sorafenib—thyroid cancer	0.00299	0.00299	CcSEcCtD
Ceftazidime—Rash—Sorafenib—thyroid cancer	0.00296	0.00296	CcSEcCtD
Ceftazidime—Dermatitis—Sorafenib—thyroid cancer	0.00296	0.00296	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00295	0.00295	CcSEcCtD
Ceftazidime—Headache—Sorafenib—thyroid cancer	0.00295	0.00295	CcSEcCtD
Ceftazidime—Pancytopenia—Epirubicin—thyroid cancer	0.0029	0.0029	CcSEcCtD
Ceftazidime—Neutropenia—Epirubicin—thyroid cancer	0.00286	0.00286	CcSEcCtD
Ceftazidime—Eosinophilia—Doxorubicin—thyroid cancer	0.0028	0.0028	CcSEcCtD
Ceftazidime—Nausea—Sorafenib—thyroid cancer	0.00279	0.00279	CcSEcCtD
Ceftazidime—Infestation NOS—Epirubicin—thyroid cancer	0.00272	0.00272	CcSEcCtD
Ceftazidime—Infestation—Epirubicin—thyroid cancer	0.00272	0.00272	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.0027	0.0027	CcSEcCtD
Ceftazidime—Pancytopenia—Doxorubicin—thyroid cancer	0.00268	0.00268	CcSEcCtD
Ceftazidime—Renal failure—Epirubicin—thyroid cancer	0.00268	0.00268	CcSEcCtD
Ceftazidime—Jaundice—Epirubicin—thyroid cancer	0.00266	0.00266	CcSEcCtD
Ceftazidime—Neutropenia—Doxorubicin—thyroid cancer	0.00264	0.00264	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00258	0.00258	CcSEcCtD
Ceftazidime—Agranulocytosis—Epirubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Ceftazidime—Infestation—Doxorubicin—thyroid cancer	0.00252	0.00252	CcSEcCtD
Ceftazidime—Infestation NOS—Doxorubicin—thyroid cancer	0.00252	0.00252	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.0025	0.0025	CcSEcCtD
Ceftazidime—Renal failure—Doxorubicin—thyroid cancer	0.00248	0.00248	CcSEcCtD
Ceftazidime—Haemoglobin—Epirubicin—thyroid cancer	0.00246	0.00246	CcSEcCtD
Ceftazidime—Jaundice—Doxorubicin—thyroid cancer	0.00246	0.00246	CcSEcCtD
Ceftazidime—Haemorrhage—Epirubicin—thyroid cancer	0.00245	0.00245	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00238	0.00238	CcSEcCtD
Ceftazidime—Agranulocytosis—Doxorubicin—thyroid cancer	0.00235	0.00235	CcSEcCtD
Ceftazidime—Erythema multiforme—Epirubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Ceftazidime—Haemoglobin—Doxorubicin—thyroid cancer	0.00227	0.00227	CcSEcCtD
Ceftazidime—Flushing—Epirubicin—thyroid cancer	0.00227	0.00227	CcSEcCtD
Ceftazidime—Haemorrhage—Doxorubicin—thyroid cancer	0.00226	0.00226	CcSEcCtD
Ceftazidime—Angiopathy—Epirubicin—thyroid cancer	0.00222	0.00222	CcSEcCtD
Ceftazidime—Immune system disorder—Epirubicin—thyroid cancer	0.00221	0.00221	CcSEcCtD
Ceftazidime—Erythema multiforme—Doxorubicin—thyroid cancer	0.00214	0.00214	CcSEcCtD
Ceftazidime—Flushing—Doxorubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Ceftazidime—Dysgeusia—Epirubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Ceftazidime—Angiopathy—Doxorubicin—thyroid cancer	0.00205	0.00205	CcSEcCtD
Ceftazidime—Immune system disorder—Doxorubicin—thyroid cancer	0.00204	0.00204	CcSEcCtD
Ceftazidime—Vision blurred—Epirubicin—thyroid cancer	0.00201	0.00201	CcSEcCtD
Ceftazidime—Agitation—Epirubicin—thyroid cancer	0.00196	0.00196	CcSEcCtD
Ceftazidime—Dysgeusia—Doxorubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Ceftazidime—Leukopenia—Epirubicin—thyroid cancer	0.00191	0.00191	CcSEcCtD
Ceftazidime—Vision blurred—Doxorubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Ceftazidime—Convulsion—Epirubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Ceftazidime—Agitation—Doxorubicin—thyroid cancer	0.00181	0.00181	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.0018	0.0018	CcSEcCtD
Ceftazidime—Leukopenia—Doxorubicin—thyroid cancer	0.00176	0.00176	CcSEcCtD
Ceftazidime—Anaphylactic shock—Epirubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Ceftazidime—Convulsion—Doxorubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Ceftazidime—Nervous system disorder—Epirubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Ceftazidime—Thrombocytopenia—Epirubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Ceftazidime—Skin disorder—Epirubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00167	0.00167	CcSEcCtD
Ceftazidime—Hypotension—Epirubicin—thyroid cancer	0.00162	0.00162	CcSEcCtD
Ceftazidime—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00161	0.00161	CcSEcCtD
Ceftazidime—Nervous system disorder—Doxorubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Ceftazidime—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Ceftazidime—Skin disorder—Doxorubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Ceftazidime—Paraesthesia—Epirubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Ceftazidime—Hypotension—Doxorubicin—thyroid cancer	0.0015	0.0015	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.0015	0.0015	CcSEcCtD
Ceftazidime—Pain—Epirubicin—thyroid cancer	0.00149	0.00149	CcSEcCtD
Ceftazidime—Paraesthesia—Doxorubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Ceftazidime—Urticaria—Epirubicin—thyroid cancer	0.00138	0.00138	CcSEcCtD
Ceftazidime—Pain—Doxorubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Ceftazidime—Abdominal pain—Epirubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Ceftazidime—Body temperature increased—Epirubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Ceftazidime—Hypersensitivity—Epirubicin—thyroid cancer	0.00128	0.00128	CcSEcCtD
Ceftazidime—Urticaria—Doxorubicin—thyroid cancer	0.00128	0.00128	CcSEcCtD
Ceftazidime—Body temperature increased—Doxorubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Ceftazidime—Abdominal pain—Doxorubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Ceftazidime—Pruritus—Epirubicin—thyroid cancer	0.00123	0.00123	CcSEcCtD
Ceftazidime—Diarrhoea—Epirubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Ceftazidime—Hypersensitivity—Doxorubicin—thyroid cancer	0.00118	0.00118	CcSEcCtD
Ceftazidime—Dizziness—Epirubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Ceftazidime—Pruritus—Doxorubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Ceftazidime—Vomiting—Epirubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Ceftazidime—Diarrhoea—Doxorubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Ceftazidime—Rash—Epirubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Ceftazidime—Dermatitis—Epirubicin—thyroid cancer	0.00109	0.00109	CcSEcCtD
Ceftazidime—Headache—Epirubicin—thyroid cancer	0.00109	0.00109	CcSEcCtD
Ceftazidime—Dizziness—Doxorubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Ceftazidime—Nausea—Epirubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Ceftazidime—Vomiting—Doxorubicin—thyroid cancer	0.00102	0.00102	CcSEcCtD
Ceftazidime—Rash—Doxorubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Ceftazidime—Dermatitis—Doxorubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Ceftazidime—Headache—Doxorubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Ceftazidime—Nausea—Doxorubicin—thyroid cancer	0.000955	0.000955	CcSEcCtD
